febuxostat has been researched along with Diabetic Glomerulosclerosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Douguchi, S; Hosoya, M; Katoh, M; Ofuchi, K; Osonoi, T; Saito, M | 1 |
| Chang, YK; Choi, WJ; Hong, YA; Kim, SY; Park, CW; Yang, KJ | 1 |
| Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T | 1 |
| Ihm, CG; Jeong, KH; Kim, YG; Lee, HJ; Lee, SH; Lee, TW; Moon, JY; Sung, JY | 1 |
| Ashizawa, N; Iwanaga, T; Morimoto, N; Murase, T; Nakamura, T; Nampei, M; Sakamoto, R | 1 |
| Komers, R; Oyama, TT; Schneider, J; Xu, B | 1 |
6 other study(ies) available for febuxostat and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Febuxostat; Humans; Hyperuricemia; Indican; Prospective Studies; Uric Acid; Uricosuric Agents | 2022 |
Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Topics: Animals; Diabetic Nephropathies; Endothelial Cells; Febuxostat; Humans; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; RNA, Messenger; Signal Transduction; Uric Acid; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xanthine Oxidase | 2023 |
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Febuxostat; Glucose Intolerance; Hyperglycemia; Hyperuricemia; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Kidney Glomerulus; Mice; Mice, Inbred C57BL; Mice, Obese; Oxidative Stress; Peptide Fragments; Uric Acid; Xanthine Oxidase | 2019 |
Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Antibiotics, Antineoplastic; Cyclooxygenase 2; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ectodysplasins; Febuxostat; Gout Suppressants; Kidney; Liver; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2014 |
Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Topics: Albuminuria; Animals; Diabetic Nephropathies; Enzyme Inhibitors; Febuxostat; Male; Mice; Nitriles; Pyridines; Xanthine Dehydrogenase | 2016 |
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Enzyme Inhibitors; Febuxostat; Male; Oxidative Stress; Rats; Rats, Zucker; Xanthine Oxidase | 2016 |